Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Drug Profile

Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Alternative Names: Adipose-derived mesenchymal progenitor cell therapy - Cellular Biomedicine Group; haMPC; MPC; ReJoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group; Shanghai Jiao Tong University
  • Class Antiasthmatics; Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cartilage disorders; Osteoarthritis
  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 12 Sep 2019 NMPA accepts an IND application for a prospective phase II trial in Osteoarthritis (of the knee) in China (Intra-articular)
  • 12 Sep 2019 Cellular Biomedicine Group plans a phase II trial in Osteoarthritis (of the knee) in China (Intra-articular)
  • 28 Dec 2018 No recent reports of development identified for preclinical development in Asthma in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top